S. North

发表

Abiraterone and increased survival in metastatic prostate cancer.

Arturo Molina, Tina Cheng, Fred Saad, 2011, The New England journal of medicine.

The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone

F. Saad, P. Karakiewicz, E. Winquist, 2008, BJU international.

Recommendations for long-term monitoring in primary care ( all recommendations Level

Ronald B. Moore, F. Saad, J. Chin, 2016 .

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Ronald B. Moore, F. Saad, J. Chin, 2016, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

T. Choueiri, B. Rini, M. Tan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.

M. Nykter, A. Wyatt, B. Tran, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

C. Porta, T. Choueiri, A. Hansen, 2019, European urology oncology.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

Y. Lotan, C. Dinney, T. Morgan, 2018, World Journal of Urology.

The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study

S. Crabb, S. Sridhar, S. North, 2018, Bladder cancer.

Oncologists of Canada consensus statement : Management of unresectable locally advanced and metastatic urothelial carcinoma

L. Eapen, P. Black, C. Booth, 2019 .

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

P. Black, A. Eisen, I. Cagiannos, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

T. Choueiri, G. De Velasco, C. Kollmannsberger, 2016, Cancer.

The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy

S. Sridhar, S. North, Z. Veitch, 2022, Therapeutic advances in medical oncology.

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

T. Choueiri, N. Agarwal, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada

S. North, B. Shayegan, F. Saad, 2022, Journal of medical economics.

A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.

Sunita Ghosh, S. North, T. Cheng, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.

T. Choueiri, B. Rini, J. Knox, 2013, Clinical genitourinary cancer.

Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer

Sunita Ghosh, M. Sawyer, Alisha Shivji, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Genitourinary small-cell carcinoma: a single-institution experience.

Sunita Ghosh, A. Dechaphunkul, N. Pervez, 2013, Current oncology.

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

L. Eapen, P. Black, C. Booth, 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

M. Gleave, F. Saad, É. Vigneault, 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

M. Gleave, F. Saad, É. Vigneault, 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

F. Saad, É. Vigneault, A. Finelli, 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.

M. Gleave, F. Saad, C. Catton, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.

S. Hotte, B. Eigl, K. Chi, 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Malignant spinal cord compression secondary to testicular seminoma at the time of initial presentation and at relapse while on surveillance.

Ronald B. Moore, D. Yee, Z. Gabos, 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

F. Saad, A. Kapoor, S. Hotte, 2011, Current oncology.

Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Ronald B. Moore, F. Saad, L. Eapen, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer

F. Saad, D. Dearnaley, J. Nelson, 2007, Cancer.

The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.

T. Choueiri, N. Agarwal, S. Srinivas, 2014, European urology.

Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study

D. O’Sullivan, N. Basappa, S. North, 2022, CMAJ open.

A randomized, phase III, double-blind, placebo-controlled trial of intrapleural instillation of methylprednisolone acetate in the management of malignant pleural effusion.

J. Mackey, H. Au, S. North, 2003, Chest.

Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study.

P. Jurasz, M. Radomski, S. North, 2003, Thrombosis research.

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

P. Karakiewicz, S. Hotte, G. Bjarnason, 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

P. Karakiewicz, R. Breau, A. Kapoor, 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Discontinuing VEGF‐targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second‐line Therapies in Metastatic Renal Cell Carcinoma

J. Brugarolas, T. Choueiri, N. Agarwal, 2017, Clinical genitourinary cancer.

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.

T. Choueiri, S. Srinivas, B. Rini, 2014, Clinical genitourinary cancer.

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.

T. Choueiri, S. Srinivas, B. Rini, 2014, Clinical genitourinary cancer.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013.

Ronald B. Moore, P. Black, C. Gedye, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

T. Choueiri, B. Rini, M. Tan, 2014, Clinical genitourinary cancer.

First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

A. Kapoor, S. Hotte, G. Bjarnason, 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Canadian consensus guidelines for the management of testicular germ cell cancer.

R. Huddart, P. Albers, P. Warde, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.

G. Pond, P. Albers, N. Agarwal, 2016, Clinical genitourinary cancer.

Perioperative chemotherapy for muscle invasive bladder cancer

N. Basappa, S. North, J. Rudzinski, 2015, Current opinion in supportive and palliative care.

Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.

Sunita Ghosh, S. North, P. Venner, 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.

J. Mackey, C. Cass, Sunita Ghosh, 2014, The Journal of urology.

Handbook of Advanced Cancer Care: Bladder cancer

H. Au, S. North, 2003 .

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

Lisa I. Wang, A. Hansen, A. Kapoor, 2019, European journal of cancer.

Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

A. Zlotta, P. Black, S. Sridhar, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Predictive Biomarkers in Muscle Invasive Bladder Cancer: Are We There Yet?

S. Sridhar, S. North, N. Blais, 2022, European urology.

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

A. Armstrong, S. Ellard, K. Chi, 2013 .

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

A. Armstrong, S. Ellard, K. Chi, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy

F. Saad, S. Hotte, E. Winquist, 2008 .

A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.

K. Graham, S. North, P. Venner, 2006, The Journal of urology.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer.

S. North, P. Venner, M. Hanninen, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c

M. Gleave, F. Saad, M. Pollak, 2011, Clinical Cancer Research.

A phase II trial of weekly i.v. KW‐2170 in advanced castrate‐resistant prostate cancer

P. de Souza, G. Bolger, S. North, 2010, Asia-Pacific journal of clinical oncology.

The Rapidly Evolving Landscape of First‐Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review

J. Lavoie, S. Sridhar, B. Eigl, 2021, The oncologist.

The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).

N. Agarwal, B. Rini, M. Tan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High fat mass associates with occurrence of targeted therapy-induced left ventricular ejection fraction reduction in patients with renal cell carcinoma.

V. Baracos, H. Becher, S. M. Kazemi-Bajestani, 2017, Clinical nutrition.

Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

Y. Lotan, C. Dinney, T. Morgan, 2022, World Journal of Urology.

Assessing the utility of cabazitaxel in mCRPC commentary

S. North, 2016 .

Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic.

S. Hotte, C. Kollmannsberger, A. Lalani, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.

S. North, P. Venner, R. C. Semeniuk, 2006, Urology.

Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer.

L. Klotz, S. Berry, Y. Ko, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients

T. Choueiri, M. Tan, C. Kollmannsberger, 2014, British Journal of Cancer.

Canadian Urologic Oncology Group (CUOG) phase II multi-center study using docetaxel/prednisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone

F. Saad, E. Winquist, S. North, 2005 .

Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.

T. Choueiri, A. Hansen, S. Hotte, 2022, European journal of cancer.

Recurrent malignant melanoma presenting with zosteriform metastases.

S. North, J. Mackey, J. Jensen, 1998, Cutis (New York, N.Y.).

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

M. Stockler, W. Parulekar, M. Frydenberg, 2019, The New England journal of medicine.

Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers

C. Butts, S. North, 2005, Expert review of vaccines.

L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer

S. North, R. Sangha, 2007, Expert opinion on biological therapy.

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

R. Lewinson, D. Heng, S. North, 2019, Cancers.

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209

H. Feilotter, L. Seymour, D. Tu, 2018, Oncotarget.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer

M. Nykter, C. Collins, S. Volik, 2017, Clinical Cancer Research.

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.

M. Nykter, M. Gleave, F. Saad, 2020, European urology.

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.

A. Tinker, A. Wyatt, L. Seymour, 2019, Clinical genitourinary cancer.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

F. Saad, H. Scher, C. Sternberg, 2012, The Lancet. Oncology.

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

E. Basch, H. Scher, C. Sternberg, 2012, The Lancet. Oncology.

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

K. Hoadley, William Y. Kim, E. Davicioni, 2017, European urology.

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

L. Seymour, H. Hirte, M. Moore, 2005, Urologic oncology.

Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada

P. Chung, P. Black, C. Booth, 2020 .

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer

C. Kollmannsberger, K. Chi, T. Griffin, 2015, Journal of clinical pharmacology.

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

T. Choueiri, B. Rini, J. Knox, 2011, The Journal of urology.

Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

T. Choueiri, N. Agarwal, S. Srinivas, 2013, Cancer.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Wanling Xie, Tina Cheng, Michael B Atkins, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies

M. Stockler, S. Sridhar, C. Sweeney, 2017, Clinical genitourinary cancer.

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

T. Choueiri, N. Agarwal, C. Kyriakopoulos, 2015, Clinical genitourinary cancer.

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

H. Scher, C. Cleeland, J. Bono, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

T. Choueiri, N. Agarwal, B. Rini, 2013, Targeted Oncology.

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

F. Saad, J. Hainsworth, H. Scher, 2015, European urology.

Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

F. Saad, A. Wyatt, S. Hotte, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, European urology.

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer

S. Ellard, S. Hotte, C. Kollmannsberger, 2012, Investigational New Drugs.

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.

Y. Lotan, C. Dinney, T. Morgan, 2019, Urologic oncology.

Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.

E. Basch, H. Scher, J. Bono, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

F. Saad, J. Hainsworth, J. Carles, 2014, European urology.

Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Yair Lotan, Todd M Morgan, Joshua Griffin, 2015, European urology.

Quality indicators in the management of bladder cancer: A modified Delphi study.

Ronald B. Moore, F. Saad, J. Chin, 2017, Urologic oncology.

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.

B. Ahmad, A. Sahgal, H. Soliman, 2021, European urology.

Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials

D. Quinn, G. Bjarnason, S. Sridhar, 2020, American journal of clinical oncology.

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

F. Saad, L. Eapen, C. Morash, 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)

M. Eliasziw, B. Eigl, E. Winquist, 2016, Investigational New Drugs.

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

I. Tannock, M. Gleave, F. Saad, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.

T. Choueiri, N. Agarwal, B. Rini, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

T. Choueiri, N. Agarwal, S. Srinivas, 2014, European urology.

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

T. Choueiri, N. Agarwal, S. Srinivas, 2012, The Lancet. Oncology.

Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.

T. Choueiri, N. Agarwal, B. Rini, 2015, Clinical genitourinary cancer.

Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study.

M. Regan, B. Rini, J. Knox, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining cisplatin eligibility in patients with muscle-invasive bladder cancer

S. Sridhar, Shilpa Gupta, S. North, 2021, Nature Reviews Urology.

Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.

Y. Lotan, C. Dinney, T. Morgan, 2020, European urology focus.

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.

Y. Lotan, C. Dinney, T. Morgan, 2020, Urologic oncology.

Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

J. Hainsworth, H. Scher, J. Bono, 2013 .

7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study

H. Scher, J. Bono, C. Sternberg, 2011 .

PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).

F. Saad, C. Albany, M. Fleming, 2017 .

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

E. Eisenhauer, J. Squire, S. Sridhar, 2015, Investigational New Drugs.

Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).

I. Tannock, A. Hansen, A. Kapoor, 2015 .

A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC).

S. Hotte, B. Eigl, D. Heng, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer.

I. Tannock, F. Saad, E. Eisenhauer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer

Y. Lotan, C. Dinney, T. Morgan, 2021, The Journal of urology.

Management of kidney cancer: canadian kidney cancer forum consensus update 2011.

P. Black, J. Dancey, G. Yousef, 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.

T. Choueiri, B. Rini, J. Knox, 2010, Urology.

Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.

A. Zlotta, T. Panzarella, P. Black, 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.

R. Breau, M. Jewett, G. Bjarnason, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.

T. Choueiri, N. Agarwal, B. Rini, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.

M. Stockler, W. Parulekar, M. Frydenberg, 2023, The Lancet. Oncology.

NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).

A. Tinker, E. Eisenhauer, S. Ellard, 2013 .

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

M. Gleave, F. Saad, É. Vigneault, 2021, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial.

M. Stockler, K. Ding, W. Parulekar, 2020, JAMA oncology.

Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa): Results of a Multi-institutional Randomized Prospective Clinical Trial

L. Wood, D. Wilke, S. North, 2013, American journal of clinical oncology.

Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.

J. Hainsworth, H. Scher, E. Small, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma

Y. Lotan, C. Dinney, T. Morgan, 2020, BJU international.

Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort

Y. Lotan, C. Dinney, T. Morgan, 2023, The Journal of urology.

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

F. Saad, G. Sonpavde, E. Antonarakis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium.

T. Choueiri, N. Agarwal, S. Srinivas, 2013 .

Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.

T. Choueiri, N. Agarwal, B. Rini, 2012 .

Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.

T. Choueiri, B. Rini, G. Bjarnason, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, G. Sonpavde, E. Antonarakis, 2016 .

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, H. Scher, C. Logothetis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

C. Porta, T. Choueiri, A. Hansen, 2018 .

Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.

M. Latour, D. Taussky, S. Hotte, 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)

I. Tannock, F. Saad, E. Eisenhauer, 2009 .

M. Stockler, L. Horvath, I. Davis, 2019, Annals of Oncology.

F. Saad, H. Scher, C. Logothetis, 2012, Journal of Clinical Oncology.

Prediction of survival benefit from docetaxel chemotherapy with PSA response and PSA half-life in men with metastatic hormone refractory prostate cancer

S. North, P. Venner, M. Hanninen, 2008 .

A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC).

A. Wyatt, B. Tran, M. Annala, 2018, Annals of Oncology.

Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial

K. Courneya, G. Bell, S. North, 2015, Prostate Cancer and Prostatic Disease.

Medical Oncology

S. North, S. North, 2001, Sarcoma.

Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.

T. Choueiri, M. Tan, C. Kollmannsberger, 2012, Journal of Clinical Oncology.

Medical Oncology

S. North, 2020, Definitions.

A phase II study of sorafenib in combination with bicalutamide in patients with chemo-naive hormone refractory prostate cancer (HRPC)

S. Ellard, E. Winquist, K. Chi, 2008 .

Outcome of advanced stage low grade follicular lymphomas in a population‐based retrospective cohort

R. Coupland, S. North, M. Palmer, 1999, Cancer.

Perioperative chemotherapy for muscle invasive bladder cancer

N. Basappa, S. North, J. Rudzinski, 2015, Current opinion in supportive and palliative care.

Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next?

T. Choueiri, B. Rini, J. Knox, 2009, Journal of Clinical Oncology.

A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.

B. Ahmad, A. Sahgal, H. Soliman, 2020 .

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).

T. Choueiri, N. Agarwal, B. Rini, 2012, Journal of Clinical Oncology.

Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

M. Eliasziw, E. Winquist, K. Chi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy

Y. Lotan, C. Dinney, T. Morgan, 2016 .

Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.

Y. Park, A. Bjartell, D. Olmos, 2018 .

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

F. Saad, J. Hainsworth, J. Carles, 2014, European urology.

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

I. Tannock, M. Gleave, F. Saad, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.

T. Choueiri, B. Rini, J. Knox, 2010, Urology.

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

P. Black, A. Eisen, I. Cagiannos, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

T. Choueiri, N. Agarwal, B. Rini, 2013, Targeted Oncology.

T. Choueiri, B. Rini, J. Knox, 2013, Clinical genitourinary cancer.

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).

M. Stockler, I. Davis, F. Vera-Badillo, 2015 .

First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).

T. Choueiri, S. Srinivas, B. Rini, 2013 .

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

T. Choueiri, B. Rini, M. Tan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib

B. Rini, R. Bukowski, Jorge A. Garcia, 2008 .

Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.

S. Tyldesley, S. Hotte, P. Chung, 2022, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials

D. Quinn, G. Bjarnason, S. Sridhar, 2017, American journal of clinical oncology.

Intermittent LHRH Therapy in the Management of Castrate-resistant Prostate Cancer (CRPCa): Results of a Multi-institutional Randomized Prospective Clinical Trial

D. Wilke, S. North, T. Cheng, 2013, American journal of clinical oncology.

Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).

T. Choueiri, N. Agarwal, A. Hansen, 2021 .